Small molecule · developed by Intensity Therapeutics
INT230-6 is a fixed-dose combination of cisplatin, vinblastine and SHAO. It is being studied in soft tissue sarcoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06263231 | Phase 3 | Sarcoma,Soft Tissue | Recruiting | INTS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Sarcoma,Soft Tissue
Updated Oct 18, 2026. Something wrong or missing? Report it on the INTS page.
See INTS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INTS catalysts and pipeline →